Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevaciz

Trial Details

NCT ID
NCT05231122
Phase
PHASE2
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • Bevacizumab
  • Pembrolizumab
  • Quality-of-Life Assessment
  • Questionnaire Administration
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age \>= 18 years of age.
  • Recurrent serous (low grade or high grade), endometrioid, or clear cell recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Participant can be either platinum-sensitive or platinum-resistant, no more than 4 prior lines of treatment, and BRCA status must be known.
  • Neoadjuvant + adjuvant is considered one line.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →